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Preadmission administration of antibiotics to patients with suspected meningococcal infection has decreased
the likelihood of obtaining an isolate and has stimulated development of rapid and reliable non-culture-based
diagnostic methods. The sensitivity of the conventional test card latex agglutination test (TCLAT) for detection
of capsular polysaccharide has been reported to be suboptimal. In the United Kingdom meningococcal DNA
detection by PCR has become readily available and is now used as a first-line investigation. Recently, the
performance of latex antigen detection has been markedly improved by ultrasound enhancement. Three tests
for laboratory confirmation of meningococcal infection, (i) PCR assays, (ii) TCLAT, and (iii) ultrasound-
enhanced latex agglutination test (USELAT), were compared in a retrospective study of 125 specimens (serum,
plasma, and cerebrospinal fluid specimens) from 90 patients in whom meningococcal disease was suspected on
clinical grounds. Samples were from patients with (i) culture-confirmed meningococcal disease, (ii) culture-
negative but PCR-confirmed meningococcal disease, and (iii) clinically suspected but non-laboratory-con-
firmed meningococcal disease. USELAT was found to be nearly five times more sensitive than TCLAT.
Serogroup characterization was obtained by both PCR and USELAT for 44 samples; all results were concor-
dant and agreed with the serogroups determined for the isolates when the serogroups were available. For 12
samples negative by USELAT, the serogroup was determined by PCR; however, for 12 other specimens for
which PCR had failed to indicate the serogroup, USELAT gave a result. USELAT is a rapid, low-cost method
which can confirm a diagnosis, identify serogroups, and guide appropriate management of meningococcal
disease contacts. A complementary non-culture-based confirmation strategy of USELAT for local use sup-
ported by a centralized PCR assay service for detection of meningococci would give the benefits of timely
information and improved epidemiological data.
Growth of Neisseria meningitidis from a normally sterile site
has long been the definitive test for the diagnosis of meningo-
coccal disease, although microscopy of Gram-stained films of
cerebrospinal fluid (CSF) can demonstrate the presence of
diplococci and strongly supports the diagnosis. The recent
trend in the United Kingdom to preadmission administration
of antibiotics to patients with suspected cases of meningococ-
cal disease coupled with a greater circumspection about ob-
taining CSF from patients in whom the clinical picture is typ-
ical has decreased the likelihood of culture confirmation (6).
Rapid, non-culture-based methods for determination of the
causative meningococcal serogroup have been developed to
improve epidemiological information and to guide contact
management by chemoprophylaxis and vaccination. PCR-
based DNA detection (9, 21, 23, 24, 25, 26) represents an
improvement in non-culture-based serogroup confirmation
over that currently available through capsular polysaccharide
detection by the conventional test card latex agglutination test
(TCLAT).
The Public Health Laboratory Service (PHLS) Meningococ-
cal Reference Unit (MRU) for England and Wales is screening
more than 10,000 samples per annum using a sensitive and
specific PCR assay (ctrA assay) to detect meningococcal DNA
(20). The ctrA-reactive specimens are further tested by the
siaD serogroup B and C PCR assays (5). The siaD assay is
inherently less sensitive than the ctrA assay, with the result that
only 65 to 70% of ctrA assay-positive samples provide a sero-
group result (20).
Commercial TCLATs can be used by nonspecialist labora-
tories for the rapid detection of serogroup-specific meningo-
coccal antigen in CSF or serum with minimal preprocessing
and modest expenditure, but poor sensitivity has been reported
(12). Recently, improved performance of antigen detection has
been described by performing assays in an ultrasonic standing
wave. Latex particles suspended in the wave are subjected to
physical forces that promote formation of aggregates (8) by
increasing particle-particle contact. Enhanced agglutination
between antibody-coated microparticles in the presence of an-
tigen occurs, giving substantial increases in sensitivity of anti-
gen detection compared to that of TCLAT (14, 16, 17, 27).
Application of the ultrasound-enhanced latex agglutination
test (USELAT) for detection of capsular polysaccharide anti-
gen from N. meningitidis serogroup A, B, C, Y, and W135
strains has demonstrated sensitivity enhancements with clinical
samples without nonspecific reactivity (2, 18).
The aim of this study was to compare PCR and latex agglu-
tination tests (LATs) for the non-culture-based diagnosis of
* Corresponding author. Mailing address: PHLS Meningococcal
Reference Unit, Manchester PHL, Manchester, M20 2LR, United
Kingdom. Phone: 44 (0)1612 914628. Fax: 44 (0)1614 462180. E-mail:
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meningococcal infection and also to determine whether
USELAT testing of clinical samples could be a practical first-
line investigation in general microbiology laboratories.
(This work has been presented in part at the 38th Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, San Diego, Calif., 24 to 27 September 1998, and the 11th
Pathogenic Neisseria Conference, Nice, France, November 1998.)
MATERIALS AND METHODS
Patients and samples. One hundred twenty-five specimens from 90 patients
were studied (Table 1). All patients had clinical features consistent with menin-
gococcal infection (meningococcal meningitis and/or septicemia) as the most
probable diagnosis. Samples had been submitted to the MRU specifically for
testing by PCR assays for the detection of meningococci. Specimens were re-
trieved following storage at 280°C for examination by TCLAT and USELAT.
Primary culture and other investigations for the detection of bacterial pathogens
were performed at the laboratories that submitted the specimens. Apart from
one patient in whom Streptococcus pneumoniae was subsequently identified as
the causative organism, no etiology other than meningococci was definitively
identified. Samples negative by the meningococcus-specific PCR assays and latex
tests were not investigated further. The study samples were selected to include (i)
PCR-positive specimens from patients from whom meningococci had been cul-
tured from normally sterile sites, (ii) specimens which were positive by PCR but
which were culture negative, (iii) specimens which were positive by culture but
which were PCR negative, and (iv) PCR- and culture-negative samples.
Isolate confirmation and characterization. Isolates of N. meningitidis are re-
ceived at the PHLS MRU from nearly all culture-positive patients identified by
clinical microbiology laboratories throughout England and Wales. Strains are
confirmed to be meningococci and are characterized with a panel of antisera (1,
10, 13, 28) to define the serogroup, serotype, and serosubtype.
Molecular detection. Clinical samples for DNA-based non-culture-based di-
agnosis of meningococcal infection are submitted to MRU and are stored at 4°C
prior to testing. Template DNA is extracted from 100 ml of the clinical specimen
(CSF, serum, or plasma) with a commercial kit (DNAzol: Gibco BRL, Paisley,
Scotland) to produce 50 ml (final volume) in sterile water (sterile injectible), of
which 2 ml is used in each PCR assay.
The ctrA and siaD PCR assays used are similar to those published previously
(5, 20) but are modified for use in the automated TaqMan PCR system (Perkin-
Elmer Applied Biosystems, Warrington, United Kingdom). The closed-tube for-
mat allows direct detection of the PCR-amplified product without additional
processing (3) and minimizes the risk of contamination. The current ctrA
TaqMan primers detect meningococcal DNA from the sialic acid-containing
meningococcal serogroups, namely, B, C, Y, and W135, which covers 98 to 99%
of invasive meningococcal strains in the United Kingdom, where serogroup A
infection is rare.
Latex agglutination reagents. Commercially available latex agglutination
reagents (Wellcogen kit; Murex Diagnostics, Dartford, United Kingdom) for
the detection of meningococcal polysaccharide were used in the TCLAT and
USELAT formats. The N. meningitidis ACYW135 reagent detects four sero-
groups (serogroups A, C, Y, and W135). The N. meningitidis B-Escherichia coli
K1 monoclonal antibody latex reagent exploits the cross-reactivity of E. coli K1
and N. meningitidis serogroup B polysaccharide and, as such, is not strictly specific.
Ultrasonic equipment. The ultrasound apparatus has been described in detail
elsewhere (15, 16). Essentially, a tubular ultrasonic transducer (PCA4; Morgan
Matroc, Wrexham, United Kingdom) with a fundamental thickness resonance
frequency of 1.5 MHz was mounted as shown schematically in Fig. 1. The
transducer was driven at 4.5 MHz by the 20 Vp-p (volts peak-peak) output of an
RF amplifier (model 240L; ENI, Rochester, N.Y.). The amplifier input came
from a Hewlett-Packard 33120A frequency synthesizer.
Conventional agglutination and ultrasonic test procedure. Specimens (serum,
plasma, or CSF specimens) were prepared for processing, in accordance with
Wellcogen kit instructions, which included centrifugation and subsequent filtra-
tion to remove protein (29) with 0.2 mm-pore-size Millex-GS (Sigma Chemical
Co., Poole, United Kingdom) membrane filters when the sample volume per-
mitted. Each patient specimen was tested with N. meningitidis B-E. coli K1 and
N. meningitidis ACYW135 test latexes by using the appropriate negative controls
supplied with the kits. The manufacturer’s instructions were followed for per-
formance and interpretation of TCLAT.
In the USELATs, 25 ml of test sample was mixed on a nonadsorbing surface
with 25 ml of diluted test or control latex suspension prediluted 1 in 8 in
phosphate-buffered saline (pH 7.4). With a syringe, the reaction droplet was
immediately drawn into a 2-mm (internal diameter) glass capillary (Fisher Sci-
entific, Loughborough, United Kingdom) which was positioned on the trans-
ducer axis and sonicated for 60 s in the axial high-acoustic-pressure region of the
sound field (15). On expulsion from the capillary onto a test card, the droplet was
stirred four times to break up nonspecific aggregates formed as a result of
ultrasonic concentration. Droplets were loaded into microslides (Camlab, Cam-
bridge, United Kingdom) with a 200-mm-path-length cross section by capillarity
and were examined for agglutination by microscopy (310 objective). Samples
were scored as positive when particle agglutination clearly exceeded any slight
residual particle aggregation in control samples. The investigators who per-
formed the LATs were unaware of PCR or culture results.
RESULTS
Detection of meningococci. Table 2 demonstrates the benefit
of non-culture-based detection by comparing the number of
samples positive by the PCR screening assay (ctrA assay) and
USELAT for culture-confirmed and culture-unconfirmed sam-
ples. The total numbers positive by the ctrA PCR assay and
USELAT were 77 (62%) and 61 (49%), respectively, whereas
42 (34%) samples were positive by culture. Forty-five ctrA PCR
assay-positive and 32 USELAT-positive samples were found
among 83 samples from culture-negative patients.
Thirty-five specimens from patients with clinically suspected
cases of meningococcal infection were culture negative and
negative or nonreactive by both PCR and USELAT (Table 2).
Eight samples were from patients with meningococcal infec-
tions that were confirmed by culture but negative for menin-
gococcal polysaccharide and DNA; three of the samples were
from a single patient with culture-proven serogroup 29E me-
TABLE 1. Samples used in the study
N. meningitidis
culture result
No. of samples (no. of patients)
Serum or plasma CSFa
Positive 37b (21c) 5 (5)
Negative 76d (55e) 7 (7)
Total 113 (78) 12 (12)
a CSF samples were from 12 patients, 9 of whom also had one or more serum
or plasma samples tested.
b Includes one sample that was positive for meningococcal serogroup Y by
culture and three samples that were positive for meningococcal serogroup 29E by
culture.
c One patient each with culture-proven meningococcal serogroup Y and sero-
group 29E infection.
d One sample was culture positive for S. pneumoniae.
e One patient had invasive S. pneumoniae infection.
FIG. 1. Section through the ultrasonic chamber showing the tubular trans-
ducer (dimensions: height, inside diameter, 20 mm; 31.5 mm; and wall thickness,
1.9 mm) and reservoir which was filled with distilled water up to a level about
1 mm from the transducer’s upper edge. The test sample is shown within the glass
capillary, which is held on the transducer axis by a central hole in the perspex lid
(not shown) and the lower locating well. The transducer was driven in radial
resonance by connecting the output from an RF voltage generator to the elec-
trodes of the inner and outer walls of the transducer.
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ningococcal infection. Neither PCR assays nor USELAT iden-
tifies serogroup 29E.
Twenty-seven (64%) samples from patients with culture-
proven cases of meningococcal infection were positive by both
USELAT and PCR. There were no discrepancies in the sero-
group results obtained. The value and complementarity of the
two non-culture-based methods were demonstrated by the re-
sults for culture-negative specimens, for which either or both
USELAT and the PCR assay were positive (Table 2). Within
the culture-unconfirmed subset of samples, 29 samples were
positive by both PCR and USELAT. In addition 16 PCR-
positive samples were USELAT negative and 3 PCR-negative
specimens were USELAT positive (Table 2).
Serogrouping of N. meningitidis infection by PCR and
USELAT. There were 56 siaD PCR-positive samples (32 sero-
group B-positive samples and 24 serogroup C-positive sam-
ples). USELAT indicated the serogroup in 44 (79%) speci-
mens for which the siaD PCR assay result was positive (23 N.
meningitidis B-E. coli K1-positive samples and 21 ACYW135-
positive samples). There was complete concordance between
the USELAT and PCR serogroup identifications for 44 sam-
ples (Table 3). When considering all results, USELAT and
PCR were in agreement for 99 (79.2%) of the 125 samples
overall.
In total, 31 and 30 samples were characterized as meningo-
coccal serogroup B and serogroup ACYW135, respectively, by
USELAT (Table 3). Twelve specimens in which the serogroup
was not determined by the siaD PCR assay were positive by the
ctrA PCR assay when USELAT indicated the causative sero-
group involved (5 ACYW135-positive specimens and 7 B-
E. coli K1-positive specimens).
Four samples were ACYW135 positive and one was N. men-
ingitidis B-E. coli K1 positive by USELAT when the ctrA PCR
assay was nonreactive. Three of these PCR-negative samples
were culture negative. One of the three PCR- and culture-
negative samples was plasma from a patient in whom menin-
gococcal infection had been confirmed by the ctrA PCR assay
with CSF. The other two samples were from a single patient in
whom there was no further laboratory evidence of meningo-
coccal disease.
Twenty-one samples (nine infected with serogroup B, three
infected with serogroup C, and nine infected with an undeter-
mined serogroup) were PCR (ctrA and/or siaD PCR)-positive
and USELAT negative, and five of these samples were from
patients with culture-proven cases of meningococcal disease
(Table 3).
Comparison of ultrasound-enhanced detection with the
standard test card method. Overall, 61 (49%) specimens were
positive by USELAT, whereas 13 (10%) were positive by
TCLAT. Table 4 shows that 84% (27 of 32) of the total culture-
positive and PCR-positive samples (Table 2) were positive by
USELAT, whereas 22% (7 of 32) were positive by the com-
mercial test card procedure. No discrepant serogroup results
were found by either latex agglutination method. There were
no TCLAT-positive results among the PCR-negative samples,
whereas USELAT was positive for five PCR-negative samples.
Sensitivity of meningococcal detection. By using the clinical
diagnosis of meningococcal disease as a standard, the relative
sensitivities of culture, USELAT, TCLAT, the ctrA PCR assay,
and the siaD PCR assay were 28% (26 of 90), 50% (45 of 90),
10% (9 of 90), 67% (60 of 90), and 48% (43 of 90), respec-
tively. Results for 26 patients with culture-confirmed menin-
gococcal disease and for whom the specimen from the site that
was culture positive was available for PCR and LAT gave
USELAT, TCLAT, ctrA PCR assay, and siaD PCR assay sen-
sitivities of 76% (20 of 26), 19% (5 of 26), 88% (23 of 26), and
69% (18 of 26), respectively. There were no discrepancies in
the serogroups identified in 15 patients who were positive by
culture, the siaD PCR assay, and USELAT.
DISCUSSION
Rapid laboratory confirmation of meningococcal infection
can help ensure the most appropriate patient care and contact
management to prevent secondary cases of infection. Noncul-
ture-based methods, specifically, PCR assays, have greatly im-
proved the rate of confirmation of infection in the United
Kingdom and have resulted in closer approximation of the
number of patients notified by clinicians to the office of Na-
TABLE 2. Detection of N. meningitidis in samples by ctrA PCR
assay and USELAT for patients with culture-confirmed and
non-culture-confirmed cases of clinical meningococcal infection
Culture
result
No. of samples
PCR positive PCR negative
TotalUSELAT
negative
USELAT
positive
USELAT
positive
USELAT
negative
Positive 5 27 2 8 42
Negative 16 29 3 35 83
Total 21 56 5 43 125
TABLE 3. Comparison of MRU meningococcal
PCR assays with USELAT
PCR and
result
No. of samples with the indicated result
by the following assay
PCR
N. meningitidis USELAT
B-E. coli KI
positive
ACYW135
positive
USELAT
negative
siaD positive for serotype B 32 23 0 9
siaD positive for serotype C 24 0 21 3
ctrA positive (siaD negative) 21 7 5a 9
PCR negative (ctrA negative) 48 1 4 43b
a Includes one sample positive for meningococcal serogroup Y by culture.
b Includes three samples positive for meningococcal serogroup 29E by culture
and one sample positive for S. pneumoniae by culture.
TABLE 4. Detection of N. meningitidis by USELAT,
TCLAT, ctrA PCR assay, and culture
PCR result Cultureresult
No. of
samples
No. of
samples
USELAT
positive
No. of
samples
TCLAT
positive
Positive Positive 32 27 7
Negative 45 29 6
Negative Positive 10a 2 0
Negative 38b 3 0
Total tested by LAT 125 61 13
a Includes three samples taken from one patient from whom serogroup 29E
meningococci were isolated.
b Includes one serum sample from a patient with meningococcal meningitis
confirmed by PCR (ctrA PCR assay positive) with CSF and includes one sample
from a patient with invasive S. pneumoniae infection.
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tional Statistics (United Kingdom) on the basis of clinical di-
agnosis and the total number of laboratory-proven cases of
infection (7, 20). Increased confidence in the available epide-
miological information is especially important prior to the an-
ticipated introduction of serogroup C conjugate meningococ-
cal vaccines to the immunization schedule in the United
Kingdom within the next 2 years (11) so that the effect of the
new vaccine can be accurately monitored.
The comparison of USELAT and a PCR test for the detec-
tion of meningococci demonstrated that there was good con-
cordance between the results of the two assays. Overall, the
ctrA PCR screening assay yielded 13% more positive results
than USELAT. It is probably more appropriate, however, to
compare USELAT with the siaD PCR since by determining
the serogroup they provide equivalent epidemiological infor-
mation.
The siaD PCR assay detected 4% fewer positive results;
moreover, the results for small numbers of specimens could be
available more rapidly by USELAT than by the PCR. A single
USELAT result would be possible within 10 min following
boiling and filtration, which take about 20 min; each additional
test would take another 8 to 10 min. This compares with about
2.5 h for a single PCR assay. PCR assays are, however, more
efficient with large numbers of samples; results from 80 assays
can be available within 5 h, which includes the time required
for specimen processing.
When both USELAT and the siaD PCR assay were positive,
there were no discrepancies in the meningococcal serogroups
identified. USELAT provided serogroup characterization in
instances in which the PCR assays could only confirm menin-
gococcal infection and in five (4%) specimens identified me-
ningococcal antigen when the ctrA PCR screening assay had
been negative. The 12 specimens positive by USELAT (7 N.
meningitidis B-E. coli K1-positive specimens and 5 ACYW135-
positive specimens and negative by siaD PCR are balanced by
the 12 USELAT-negative samples positive by the siaD PCR
assay (9 serogroup B-infected specimens and three serogroup
C-infected specimens).
In this study of 90 patients with clinical meningococcal dis-
ease, the most sensitive test for meningococcal detection was
the ctrA PCR assay. USELAT was more sensitive than the siaD
PCR assay for serogroup confirmation, and both assays were
superior to standard LAT (with Murex reagents) and culture.
The relative positions of the sensitivities of the USELAT,
TCLAT, and the two PCR assays remained the same when the
sensitivities were determined for the subset of samples from
patients with culture-confirmed cases of infection. Previous
studies of USELAT (2) and meningococcal PCR (5) estimate
100% specificity. A single sample from a patient with an S.
pneumoniae infection and three samples from one patient in-
fected with meningococcal serogroup 29E were nonreactive by
both USELAT and PCR.
The likelihood of serogroup determination by USELAT or
the siaD PCR will be affected by the amount of target present.
PCR techniques detect unique N. meningitidis gene sequences
present as single copies on each genome, giving a lower limit
of detection (250 organisms/ml of fluid tested). In contrast,
USELAT detects extracellular capsular polysaccharide, which
is produced in excess and which blebs off the organism into the
surrounding medium. LAT was performed with 25 ml of a
1-in-4-diluted plasma or serum sample, representing approxi-
mately 6 ml of the original specimen, while the 2 ml of the DNA
extract tested by PCR was from 4 ml of plasma or serum from
the original sample. The volume of the specimen from which
target for the respective tests was obtained was therefore
equivalent.
One of the five USELAT (ACYW135)- and ctrA PCR-pos-
itive samples was found to be a culture-proven serogroup Y
infection not detected by the siaD PCR assay used. It is pos-
sible that any of the other four samples could have been from
patients with serogroup Y or W135 infection, but it is most
unlikely that any were from patients with serogroup A infec-
tions, since only two cases of infection with these globally
important strains have been identified in the United Kingdom
over the last 3 years. An alternative explanation is that the
samples contained small numbers of genome copies that were
detectable by the ctrA PCR assay but not by the siaD PCR
assay because the currently available assays exhibit different
sensitivities (20).
The sensitivities of the PCR assays may be improved by
better DNA extraction and by redesigning the TaqMan assay
to include probes for the less common serogroups that cause
infection in England and Wales. The current TaqMan ctrA
PCR assay detects serogroups B, C, W135, and Y. Serogroups
A, X, 29E, and Z are not detected by the current TaqMan ctrA
PCR assay but can be detected by a ctrA PCR and enzyme-
linked immunosorbent assay (20). The siaD primers described
previously (5) were redesigned for the TaqMan assay for in-
creased sensitivity. Serogroup Y- and W135-specific (siaD)
PCR assays have recently been developed in a PCR and en-
zyme-linked immunosorbent assay format (4) and will, in fu-
ture, be used with specimens that are positive by the ctrA PCR
assay but that are nonreactive by the serogroup B- or C-specific
siaD PCR assay.
Because of developments in the molecular characterization
of strains by the sequencing of alleles of housekeeping or outer
membrane protein-encoding genes, such assays are now able to
furnish more information than can be provided by any sero-
logically based method (22). The facility of translating se-
quencing techniques into a non-culture-based diagnostic for-
mat is being explored. Data generated in this way could
provide important additional information for the management
of clusters of infections and outbreaks.
All the LAT investigations were initially performed 2
months after the PCR assays, demonstrating that polysaccha-
ride can persist in stored specimens. In performing the tests
independently at the two study sites (Cardiff and Manchester),
the technique was found to be portable between laboratories.
Undoubted advantages of USELAT over PCR are the lower
costs in terms of labor, staff training, equipment, and reagents.
A compact voltage-generating device with the essential char-
acteristics of the test equipment described in Materials and
Methods has recently been developed (Electro-Medical Sup-
plies, Wantage, United Kingdom). The performance of the
device is under evaluation at six hospital locations in the Brit-
ish Isles. If trials are successful a device could become com-
mercially available for less than $4,000. The possibility of using
the ultrasound equipment for other latex agglutination-based
assays (14, 16) would make any investment even more cost-
effective. To develop and maintain confidence on the part of
both operators and end users as to the validity of the test
results, it would be necessary to develop an external quality
assurance scheme (perhaps comprising a panel of negative
material and stringently quantified meningococcal polysaccha-
ride samples weighted to include a high proportion of samples
containing amounts close to detection thresholds).
Ultrasound assays with individual serogrouping latex re-
agents for serogroups A, C, Y, and W135 (currently commer-
cially available from Sanofi and bioMerieux) are under evalu-
ation to see if it is possible to provide specific information on
the serogroup. Performance of the test with the serogroup-
specific latex agglutination reagent after demonstration of re-
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activity with the pooled reagent would be efficient and cost-
effective. Knowledge of the local serogroup incidence would
dictate the sequence in which such specific assays were per-
formed. A DNA-based detection strategy would require five
separate PCR assays (meningococcal DNA detection, followed
by detection of DNAs of serogroups B, C, Y, and W135), and
the cost would be considerably greater than those of the LATs.
Although the increased overall sensitivity of the ctrA PCR
assay over that of USELAT was clearly shown in this study, the
latter would be an extremely useful method of case confirma-
tion in those countries where rapid PCR diagnosis is unavail-
able. USELAT could notably improve the epidemiological
data from areas of the world where routine culture is often
impracticable.
USELAT could be used as a first-line investigation in local
microbiology laboratories (19) for rapid non-culture-based di-
agnosis with relevant clinical samples collected as soon after
admission as possible. Potentially helpful additional informa-
tion can be obtained from PCR-based testing schemes, and this
will increase over the next few years. When meningococcal
PCR assays are available, as is currently the case at reference
units in the United Kingdom and the Republic of Ireland, early
specimens from all patients with suspected meningococcal in-
fection should be sent for PCR, regardless of any other tech-
niques that are available locally.
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